|
1
|
Vaupel P: The role of hypoxia-induced
factors in tumor progression. The Oncologist. Suppl 5:S10–S17.
2004. View Article : Google Scholar
|
|
2
|
Carmeliet P: Angiogenesis in health and
disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qian F, Engst S, Yamaguchi K, Yu P, Won
KA, Mock L, Lou T, Tan J, Li C, Tam D, et al: Inhibition of tumor
cell growth, invasion, and metastasis by EXEL-2880 (XL880,
GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine
kinases. Cancer Res. 69:8009–8016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsumoto S, Miyamoto N, Hirayama T, Oki
H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, et
al: Structure-based design, synthesis, and evaluation of
imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as
novel dual c-Met and VEGFR2 kinase inhibitors. Bioorg Med Chem.
21:7686–7698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhan Z, Ai J, Liu Q, Ji Y, Chen T, Xu Y,
Geng M and Duan W: Discovery of anilinopyrimidines as dual
inhibitors of c-met and VEGFR-2: Synthesis, SAR, and cellular
activity. ACS Med Chem Lett. 5:673–678. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mizuno S and Nakamura T: Hepatocyte growth
factor: A regenerative drug for acute hepatitis and liver
cirrhosis. Regen Med. 2:161–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Molnarfi N, Benkhoucha M, Funakoshi H,
Nakamura T and Lalive PH: Hepatocyte growth factor: A regulator of
inflammation and autoimmunity. Autoimmun Rev. 14:293–303. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yap TA and de Bono JS: Targeting the
HGF/c-Met axis: State of play. Mol Cancer Ther. 9:1077–1079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang X, Zhang Y, Yang Y, Lim S, Cao Z, Rak
J and Cao Y: Vascular endothelial growth factor-dependent
spatiotemporal dual roles of placental growth factor in modulation
of angiogenesis and tumor growth. Proc Natl Acad Sci USA.
110:13932–13937. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Jiang X, Jiang Y, Guo M, Zhang S,
Li J, He J, Liu J, Wang J and Ouyang L: Recent advances in the
development of dual VEGFR and c-Met small molecule inhibitors as
anticancer drugs. Eur J Med Chem. 108:495–504. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Falco S, Gigante B and Persico MG:
Structure and function of placental growth factor. Trends
Cardiovasc Med. 12:241–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishimoto RN: OFIRMEV: An old drug becomes
new again. Anesth Prog. 61:99–102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Wu J, Gao Y, Chen H and Zhou J:
Scaffold repurposing of old drugs towards new cancer drug
discovery. Curr Top Med Chem. 16:2107–2114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai ZW, Wei D, Schroeder GM, Cornelius LA,
Kim K, Chen XT, Schmidt RJ, Williams DK, Tokarski JS, An Y, et al:
Discovery of orally active pyrrolopyridine- and aminopyridine-based
met kinase inhibitors. Bioorg Med Chem Lett. 18:3224–3229. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui JJ, McTigue M, Nambu M, Tran-Dubé M,
Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P, et al:
Discovery of a novel class of exquisitely selective
mesenchymal-epithelial transition factor (c-MET) protein kinase
inhibitors and identification of the clinical candidate
2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol
(PF-04217903) for the treatment of cancer. J Med Chem.
55:8091–8109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oguro Y, Miyamoto N, Okada K, Takagi T,
Iwata H, Awazu Y, Miki H, Hori A, Kamiyama K and Imamura S: Design,
synthesis, and evaluation of
5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: Novel
VEGFR2 kinase inhibitors binding to inactive kinase conformation.
Bioorg Med Chem. 18:7260–7273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fabian MA, Biggs WH III, Treiber DK,
Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P,
Edeen PT, Floyd M, et al: A small molecule-kinase interaction map
for clinical kinase inhibitors. Nat Biotechnol. 23:329–336. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karaman MW, Herrgard S, Treiber DK,
Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI,
Edeen PT, et al: A quantitative analysis of kinase inhibitor
selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
